Reviva Pharmaceuticals Holdings, Inc. (RVPH)
| Market Cap | 81.70M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -1.15M |
| Shares Out | 2.81M |
| EPS (ttm) | -0.54 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 26 |
| Last Price | $8.88 |
| Previous Close | $8.90 |
| Change ($) | -0.02 |
| Change (%) | -0.22% |
| Day's Open | 8.90 |
| Day's Range | 8.72 - 8.91 |
| Day's Volume | 3,093 |
| 52-Week Range | 7.92 - 11.88 |
News
Combined Company to Trade on NASDAQ Post-closing under Tickers: RVPH and RVPHW
NEW YORK, Sept. 14, 2020 /PRNewswire/ -- Tenzing Acquisition Corp.
New York, New York--(Newsfile Corp. - July 24, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who own Tenzing Acquisition Corp.
About RVPH
Reviva Pharmaceuticals Holdings, a clinical stage pharmaceutical company, develops therapies to address unmet medical needs in the areas of central nervous system, cardiovascular, metabolic, and inflammatory diseases. Its lead product candidate is RP5063 for the treatment of schizophrenia, bipolar disorder, and major depressive disorder, as well as for treating pulmonary arterial hypertension and idiopathic pulmonary fibrosis. The company is based in Cupertino, California.
| Industry Biotechnology | Founded 2006 |
| CEO Dr. Laxminarayan Bhat | Employees 5 |
| Stock Exchange NASDAQ | Ticker Symbol RVPH |